Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Licenses Geron’s Patents on Human Embryonic Stem Cells

NEW YORK, June 29 (GenomeWeb News) - Geron licensed its intellectual property related to the growth of human embryonic stem cells to Invitrogen, Invitrogen said today.

 

Under the non-exclusive license agreement, Invitrogen can use Geron's patents to develop, manufacture, and sell media, additives, and reagents for use by hESC researchers. Some commercial use restrictions apply.

 

Invitrogen can also sublicense the products to its customers for research use only. Geron will receive license payments and royalties on products developed using the patents.

 

The license involves patents covering the growth of hESCs in the absence of feeder cells, and those covering specific media formulations for such feeder-free growth.

 

Additional financial details were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.